Health care costs for state transition models in prostate cancer

Medical Decision Making

Volumn 34, Issue 3, 2014, Pages 366-378

  Krahn, Murray D ^a,b,c,e   Bremner, Karen E ^b,e   Zagorski, Brandon ^b,c   Alibhai, Shabbir M H ^a,b,c,e,f,g   Chen, Wendong ^c   Tomlinson, George ^a,b,c,d,e   Mitsakakis, Nicholas ^c   Naglie, Gary ^a,b,c,e,f,g  

^a Department of Medicine ^*  (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^g BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

costs; economic evaluation; prostate cancer

Indexed keywords

AGED; CANADA; ECONOMICS; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SOCIAL CLASS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; ONTARIO; PROSTATIC NEOPLASMS; SOCIAL CLASS;

EID: 84898792431     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X13493970     Document Type: Article

References (43)

1. FerlayJShinHRBrayFFormanDMathersCParkinDM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/. accessed on March 12, 2013.
2. Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer PD. 2009 ; 12 (4). 355-60
3. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008 ; 100: 888-97
4. Krahn MD, Zagorski B, Laporte A, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int. 2010 ; 105 (3). 338-46
5. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008 ; 100 (9). 630-41
6. Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship care. J Urol. 2010 ; 184: 532-8
7. Drummond ME, O'Brien B, Stoddart GL, Torrance GW New York: Oxford University Press ; 1997 :
8. Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 ; 28 (6). 489-505
9. Mouraviev V, Nosnik I, Sun L, et al. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007 ; 69 (2). 311-4
10. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis. 2007 ; 4 (4). 1-17
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1983 ; 13 (4). 322-38
12. Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn M. Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol. 2003 ; 21 (17). 3318-27
13. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg J. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993 ; 269: 2650-9
14. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA. 1994 ; 272: 773-80
15. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002 ; 40 (8). 104-17
16. Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009 ; 47 (7). S51-5
17. Hall S, Schulze K, Groome P, McKillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol. 2006 ; 59: 67-76
18. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis, part 5: working with Markov processes. Med Decis Making. 1997 ; 17 (2). 152-9
19. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Int Med. 1997 ; 12: 299-305
20. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. ; 2012 ; 2012. 591.
21. Canada Health Act. 22June2011. http://laws-lois.justice.gc.ca/eng/acts/c- 6/PITIndex.html
22. Jacobs P, Yim R Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health ; 2009 :
23. Wijeysundera HC, Machado M, Wang X, et al. Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada. Value Health. 2010 ; 13 (8). 915-21
24. Starfield B, Lemke KW, Bernhardt T, Foldes SS, Forrest CB, Weiner JP. Comorbidity: implications for the importance of primary care in 'case' management. Ann Fam Med. 2003 ; 1 (1). 8-14
25. Starfield B, Lemke KW, Herbert R, Pavlovich WD, Anderson G. Comorbidity and the use of primary care and specialist care in the elderly. Ann Fam Med. 2005 ; 3: 215-22
26. Hanley GE, Morgan S, Reid RJ. Explaining prescription drug use and expenditures using the Adjusted Clinical Groups Case-Mix system in the population of British Columbia, Canada. Med Care. 2010 ; 48: 402-208
27. Kralj B. Measuring "rurality" for purposes of health-care planning. Ontario Med Rev. 2000;October ;: 33-52
28. 4 th ed.Philadelphia, PA: Lippincott; 1992. Philadelphia, PA: Lippincott ; 1992 :
29. Mazzucchelli R, Nesseris I, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Active surveillance for low-risk prostate cancer. Anticancer Res. 2010 ; 30: 3683-92
30. SAS OnlineDoc: version 8. The MI procedure. Available from: http://support.sas.com/rnd/app/papers/miv802.pdf
31. SAS OnlineDoc: version 8. The MIANALYZE procedure. Available from: http://support.sas.com/rnd/app/papers/mianalyzev802.pdf
32. Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making. 1998 ; 18: S39-56
33. Duan N. Smearing estimate: a non-parametric retransformation method. J Am Stat Assoc. 1983 ; 78: 605-10
34. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998 ; 17: 283-95
35. Cooper NJ, Lambert PC, Abrams KR, Sutton AJ. Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritis. Health Econ. 2007 ; 16: 37-56
36. Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer PD. 2010 ; 13 (3). 278-84
37. Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer PD. 2010 ; 13: 162-7
38. Snyder CF, Frick KD, Blackford AL, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?. Cancer. 2010 ; 116 (23). 5391-9
39. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007 ; 109 (3). 518-27
40. Molinier L, Castelli C, Bauvin E, et al. Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data. Eur J Health Econ. 2011 ; 12: 363-71
41. Warren JL, Klabunde CN, Schrag D, Bach PB, Rily GF. Overview of SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002 ; 40 (8). 3-18
42. Pink GH, Bolley HD. Physicians in health care management, 4: case mix groups and resource intensity weights: physicians and hospital funding. CMAJ. 1994 ; 150 (8). 1255-1
43. Poon I, Pintilie M, Potvin M, McGowan T. The changing cost of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy. Can J Urol. 2004 ; 11 (1). 2125-32